Genetics and hypertension: is it time to change my practice?

Area of Science:

• Genetics
• Cardiovascular Medicine
• Pharmacology

Background:

• Recent advancements in genotyping and large-scale genome-wide association studies (GWAS) have significantly improved our understanding of the genetic underpinnings of hypertension.
• Despite progress, translating these genetic findings into clinical practice remains a key challenge.

Purpose of the Study:

• To summarize strategies for dissecting hypertension genetics, from candidate gene studies to GWAS and sequencing.
• To explore the potential of genetic data in developing novel hypertension therapeutics and personalized medicine strategies.

Main Methods:

• Review of candidate gene studies, genome-wide association studies (GWAS), and sequencing experiments.
• Analysis of therapeutic agents targeting pathways with small contributions to genetic variability.

Main Results:

• Genetic findings offer hope for developing new hypertension drugs based on novel pathophysiological principles.
• Targeting specific pathways, even those with minor genetic influence, can yield significant therapeutic effects.

Conclusions:

• Genetic data is expected to drive the development of new hypertension treatments.
• Pharmacogenetics and risk stratification hold potential but require further robust evidence and validation for clinical implementation.